Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (n-(2-methyloxy-5-(2',4',6'-trimethoxystyrylsulfonyl)methylenephenyl)amino)acetic Acid
2. N-(2-methoxy-5-((((e)-2-(2,4,6-trimethoxyphenyl)vinyl)sulfonyl)methyl)phenyl)glycine
3. On 01910
4. On 01910.na
5. On-01910
6. On01910
7. Rigosertib Sodium
8. Sodium (n-(2-methyloxy-5-(2',4',6'-trimethoxystyrylsulfonyl)methylenephenyl)amino)acetate
1. 592542-59-1
2. On-01910
3. On 01910
4. Rigosertib [usan]
5. 67dow7f9gl
6. Rigosertib (usan)
7. 2-[2-methoxy-5-[[(e)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic Acid
8. (e)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic Acid
9. N-[2-methoxy-5-({[(e)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine
10. N-[2-methoxy-5-[[[(1e)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine
11. Rigosertib [usan:inn]
12. Unii-67dow7f9gl
13. Rigosertibum
14. 6fs
15. N-(2-methoxy-5-((((1e)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)phenyl)glycine
16. Rigosertib [inn]
17. Rigosertib [who-dd]
18. Estybon (proposed Trade Name)
19. Schembl498623
20. Schembl498624
21. Gtpl7833
22. Chembl1241855
23. On01910.na
24. Dtxsid30207984
25. 2-[2-methoxy-5-[2-(2,4,6-trimethoxyphenyl)ethenylsulfonylmethyl]anilino]acetic Acid
26. Chebi:124939
27. Chebi:145417
28. Bcp08296
29. Ex-a4346
30. Zinc3942646
31. Bdbm50060917
32. Akos015966442
33. Db12146
34. Glycine, N-[2-methoxy-5-[[[(1e)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-
35. (e)-on 01910
36. 2-[[2-methoxy-5-[[(e)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]phenyl]amino]acetic Acid
37. Ac-32479
38. As-35249
39. On-01910on-01910
40. D10154
41. On-01910;on01910;on 01910
42. Brd-k55187425-236-01-1
43. Q21099552
44. (e)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic Acid
45. [2-methoxy-5-({[(e)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)anilino]acetic Acid
46. [2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)anilino]acetic Acid
47. N-(2-methoxy-5-((((1e)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) Phenyl)glycine
48. N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine
49. Glycine, N-(2-methoxy-5-((((1e)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) Methyl)phenyl)-
| Molecular Weight | 451.5 g/mol |
|---|---|
| Molecular Formula | C21H25NO8S |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 11 |
| Exact Mass | 451.13008793 g/mol |
| Monoisotopic Mass | 451.13008793 g/mol |
| Topological Polar Surface Area | 129 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 678 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
69
PharmaCompass offers a list of Rigosertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rigosertib manufacturer or Rigosertib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rigosertib manufacturer or Rigosertib supplier.
PharmaCompass also assists you with knowing the Rigosertib API Price utilized in the formulation of products. Rigosertib API Price is not always fixed or binding as the Rigosertib Price is obtained through a variety of data sources. The Rigosertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rigosertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rigosertib, including repackagers and relabelers. The FDA regulates Rigosertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rigosertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rigosertib supplier is an individual or a company that provides Rigosertib active pharmaceutical ingredient (API) or Rigosertib finished formulations upon request. The Rigosertib suppliers may include Rigosertib API manufacturers, exporters, distributors and traders.
Rigosertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rigosertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rigosertib GMP manufacturer or Rigosertib GMP API supplier for your needs.
A Rigosertib CoA (Certificate of Analysis) is a formal document that attests to Rigosertib's compliance with Rigosertib specifications and serves as a tool for batch-level quality control.
Rigosertib CoA mostly includes findings from lab analyses of a specific batch. For each Rigosertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rigosertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Rigosertib EP), Rigosertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rigosertib USP).
